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Summary
GTF2IRD2 belongs to a family of transcriptional regulators (including TFII-I and GTF2IRD1) that are responsible for many of the key
features of Williams–Beuren syndrome (WBS). Sequence evidence suggests that GTF2IRD2 arose in eutherian mammals by duplication and
divergence from the gene encoding TFII-I. However, in GTF2IRD2, most of the C-terminal domain has been lost and replaced by the
domesticated remnant of an in-frame hAT-transposon mobile element. In this first experimental analysis of function, we show that transgenic
expression of each of the three family members in skeletal muscle causes significant fiber type shifts, but the GTF2IRD2 protein causes an
extreme shift in the opposite direction to the two other family members. Mating of GTF2IRD1 and GTF2IRD2 mice restores the fiber type
balance, indicating an antagonistic relationship between these two paralogs. In cells, GTF2IRD2 localizes to cytoplasmic microtubules and
discrete speckles in the nuclear periphery.We show that it can interact directly with TFII-Ib and GTF2IRD1, and upon co-transfection changes
the normal distribution of these two proteins into a punctate nuclear pattern typical of GTF2IRD2. These data suggest that GTF2IRD2 has
evolved as a regulator of GTF2IRD1 and TFII-I; inhibiting their function by direct interaction and sequestration into inactive nuclear zones.
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Introduction
GTF2IRD2 belongs to a small family of related genes – GTF2I,
GTF2IRD1 and GTF2IRD2 – that are clustered within the
mammalian genome. The GTF2IRD2 genes in the human lie
within blocks of highly homologous low copy repeats (LCRs) that
flank a domain containing 28 genes within 7q11.23 that is
hemizygously deleted in WBS (Osborne and Mervis, 2007).
Haploinsufficiency of a subset of dosage-sensitive genes from
within the deletion region is thought to be the cause of the most
prominent features of this neurodevelopmental disorder. The
disease is typified by a set of characteristic physical, cognitive and
behavioral abnormalities. Of the 28 genes in the deleted contig, the
only proven genotype-phenotype link is that haploinsufficiency of
elastin (ELN) causes a range of connective tissue problems
including supravalvular aortic stenosis (Morris and Mervis, 2000).
Careful analysis of the features of patients carrying atypical
deletions of the region has led to the conclusion that loss of
GTF2IRD1 and GTF2I can explain most of the other principal
features including craniofacial dysmorphology, hypersociability
and visuospatial deficits (Antonell et al., 2010). Recent work
studying mice with mutations of the orthologous Gtf2ird1 and
Gtf2i genes supports this conclusion and phenotypes of
craniofacial dysmorphology (Tassabehji et al., 2005; Lucena
et al., 2010; Howard et al., 2012), reduced fear and aggression
(Young et al., 2008) and increased social interactions (Sakurai
et al., 2011) have been reported.
At least 2 copies of GTF2IRD2 have been identified in the
human as well as a GTF2IRD2 pseudogene in the centromeric
LCR containing a frameshift mutation. Due to the highly
homologous nature of the duplicated regions, some doubt
remains concerning the existence of a possible third copy
(Tipney et al., 2004). It is currently unknown whether all/both of
these genes are active at equal rates or whether only one is
responsible for generating the majority of transcripts. Since the
GTF2IRD2 genes lie within the sites where illegitimate
recombination occurs during the meiotic events that create the
WBS deletion, it is possible that GTF2IRD2 total expression is
disrupted, leading to a variable reduction of GTF2IRD2 protein in
WBS patients. On these grounds, GTF2IRD2 should be considered
as a potential causative agent in the characteristic features of WBS.
TFII-I, GTF2IRD1 and GTF2IRD2 have an N-terminal leucine
zipper and a series of highly conserved repeat domains (RDs or
I-repeats) of unclear function. These RDs, which adopt a
previously unknown fold according to NMR analysis (Doi-
Katayama et al., 2007), are unique to this family. Conservation of
the RDs between orthologs or between family members is much
higher than any other regions of the protein, suggesting that these
domains constitute an essential functional element. Some of the
RDs within GTF2IRD1 have been shown to have sequence-
specific DNA binding properties (Polly et al., 2003; Vullhorst
and Buonanno, 2005) and GTF2IRD1 protein can bind to its own
promoter region via simultaneous usage of two RDs making
5040 Research Article
J
o
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
contact with two independent DNA binding sites in the
GTF2IRD1 promoter (Palmer et al., 2010). RD2 of TFII-I has
also been associated with sequence-specific DNA binding
properties (Cheriyath and Roy, 2001; Roy, 2001). A large body
of evidence implicates TFII-I as a signal-induced transcription
factor with a variety of gene targets including c-fos (Roy, 2007).
Other evidence indicates that phosphorylated tyrosines within
RD2 and RD3 regulate a cytoplasmic interaction with PLC-c that
controls agonist-induced calcium entry (Caraveo et al., 2006). A
number of other interactions both in the cytoplasm and the
nucleus suggest a complex set of potential roles that are yet to be
refined (Casteel et al., 2002; Sacrista´n et al., 2004; Jiang et al.,
2005; Roy, 2006; Tapia-Pa´ez et al., 2008; Ren et al., 2011).
GTF2IRD2 shares strong homology with TFII-I in the N-
terminal region (Tipney et al., 2004), but it deviates from the
structure of TFII-I and GTF2IRD1 in two main ways. Firstly, it
only has two RDs, which are most similar in sequence to RD1
and RD6 of TFII-I (Makeyev et al., 2004). Secondly, the C-
terminal half of the protein is encoded by a single large exon that
has derived from the insertion of a CHARLIE8 transposon
element (Tipney et al., 2004) belonging to the hAT class (Rubin
et al., 2001), which is in-frame with the N-terminal truncated
TFII-I-like portion. This process has, therefore, removed the
equivalents of RDs 2–5, containing the presumed DNA-binding
domain, the phosphorylation sites in RD2 and 3 and the nuclear
localization signal. It is therefore difficult to predict what
function GTF2IRD2 may perform based on evolutionary history
and sequence homology alone.
In this study we examine the hypothesis that GTF2IRD2 has
retained some functional overlap with GTF2IRD1 and TFII-I, but
has acquired new properties bestowed by the acquisition and
adaptation of a randomly inserted mobile DNA element. To
examine GTF2IRD2 function, we considered using the assays
that have been previously applied to GTF2IRD1 and TFII-I, but
most are based on specific assumptions concerning known gene
targets and known mechanisms of transcriptional regulation
(Manzano-Winkler et al., 1996; Kim et al., 1998; Tantin et al.,
2004; Tapia-Pa´ez et al., 2008), the nature and sequence
specificity of DNA binding (O’Mahoney et al., 1998;
Bayarsaihan and Ruddle, 2000; Calvo et al., 2001; Ring et al.,
2002; Polly et al., 2003; Vullhorst and Buonanno, 2003;
Vullhorst and Buonanno, 2005; Palmer et al., 2010) or
specifically identified protein–protein interactions (Roy et al.,
1993; Novina et al., 1999; Casteel et al., 2002; Sacrista´n et al.,
2004; Jiang et al., 2005; Caraveo et al., 2006). In this case, it was
not possible to make specific assumptions about mechanism of
GTF2IRD2 action based on sequence similarity alone as the
protein has diverged significantly. Therefore, we elected to
utilize a skeletal-muscle-specific transgenic expression model
system to compare the regulatory relationship between the
members of this gene family since we previously published
regulation of skeletal muscle fiber type by GTF2IRD1 (Issa et al.,
2006). We show that GTF2IRD2 does impact on fiber-specific
gene expression and has an antagonistic effect on skeletal muscle
fiber type conversion compared to GTF2IRD1 and TFII-Ib. In
cell culture, we find that GTF2IRD2 localizes to microtubules
and to distinct punctate nuclear domains. When GTF2IRD1 and
TFII-Ib are also present, these proteins colocalize with the
GTF2IRD2 punctate nuclear domains. We show that GTF2IRD2
can interact directly with both GTF2IRD1 and TFII-Ib. Our
findings are consistent with a mechanism in which GTF2IRD2
regulates the activity of GTF2IRD1 and TFII-I proteins by direct
interaction and sequestration of the proteins to a novel nuclear
compartment.
Results
Evolutionary history and conservation of the
GTF2IRD2 gene
Previous work has shown that GTF2IRD2 shares strong sequence
homology with the protein TFII-I (Hinsley et al., 2004; Tipney
et al., 2004) and their encoding genes (GTF2IRD2 and GTF2I)
are located near to each other on human chromosome 7
(Fig. 1A).
Analysis of current genome sequence from a variety of
vertebrate species indicates that GTF2IRD2 arose after the
emergence of mammals, but prior to the radiation of the
eutherian lineages. This is based on comparison of conservation
of synteny in the region surrounding the GTF2I gene in various
species (Fig. 1A). GTF2IRD2 is not present in non-mammalian
vertebrates or in the opossum as a representative of the marsupials.
However, it is present in all of the eutherian mammals for which
there is good sequence data in this region. It is likely that
GTF2IRD2 has arisen as a result of duplication of the GTF2I gene,
insertion of an in-frame CHARLIE8 transposon and subsequent
sequence divergence.
Strong conservation of the GTF2IRD2 protein sequence across
all eutherian mammals suggests that this newly evolved gene has
stabilized in all placental mammals and retains a functional
importance that has been maintained (Fig. 1B). Sequence
conservation within the CHARLIE8 transposon fossil domain
(81% identity between human and mouse) is equivalent to the N-
terminal half of the protein (76% identity human/mouse),
suggesting that this region plays an equally important role in
the function of GTF2IRD2.
Expression of TFII-I and GTF2IRD2 in muscle causes
opposite fiber type shifts
Our previous work involving the transgenic expression of the
GTF2IRD1 protein in muscle tissue proved a powerful means to
show the repressive properties of GTF2IRD1 on slow fiber-
specific gene expression and revealed a potential role for
GTF2IRD1 in the development of skeletal muscle tissue (Issa
et al., 2006). Gtf2ird2 is ubiquitously expressed (Tipney et al.,
2004) and thus a potential role in muscle tissue could also emerge
from this assay. The transgenic muscle-specific expression model
was used as a means to assess GTF2IRD2 function alongside the
b-isoform of TFII-I for comparative purposes. The mouse
Gtf2ird2 ORF was cloned into an expression plasmid driven by
the human skeletal actin (HSA) promoter/enhancer from the
ACTA1 gene that drives high levels of expression exclusively in
skeletal muscle tissue (Brennan and Hardeman, 1993). An ORF
(Gtf2ib) encoding the mouse b-isoform of TFII-I (Roy, 2001)
was cloned into the same vector so that direct phenotypic
comparisons could be made between the activity of the two
ancestral derivatives. The b-isoform of TFII-I was chosen
because it is abundant in mouse tissues and has been shown to
bind to target genes under basal conditions whereas other
isoforms are known to require growth factor signaling-induced
activation to achieve nuclear localization and DNA binding
(Hakre et al., 2006).
Transgenic founder lines were analyzed by northern blot for
levels of transgene expression and Southern blot genome
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fragment patterns for possible multiple insertion sites (data not
shown). Three independent founder lines, based on high, medium
and low expression levels, were selected for further study. All
data presented are from the highest expressing GTF2IRD2 and
TFII-Ib lines, but phenotypes were consistent in the lower
expressing lines; the degree of the phenotype correlating roughly
with the level of transgene expression (data not shown).
In adult TFII-Ib transgenic mice, muscle histology appeared
normal, but analysis of fiber type composition in whole
transverse sections of the lower hind limb (crural block)
revealed a marked decrease in the number of MyHC type I
fibers in the soleus muscle and the surrounding muscles and a
concomitant increase in the number of MyHC type IIA fibers
both within and outside the soleus muscle compared to wild-type
controls (Fig. 2A). This result is very similar to the consequences
of human GTF2IRD1 expression in muscle tissue; although, the
degree is less extreme (Fig. 2A). In GTF2IRD1 transgenic
animals, virtually all MyHC type I fibers are undetectable by 8
weeks after birth (Issa et al., 2006).
In contrast, analysis of fiber type patterning in the crural block
of adult GTF2IRD2 transgenic mice revealed the opposite result
to TFII-Ib and GTF2IRD1 expression. A significant increase in
MyHC type I fibers was found in the soleus muscle and the
surrounding muscles compared to wild-type controls,
accompanied by a reduction in the numbers of fast type IIa
fibers (Fig. 2A). In GTF2IRD1 transgenic animals, it was shown
that the fiber type shift was not due to alterations in embryonic
patterning events, but due to post-natal conversion mechanisms
(Issa et al., 2006). Similarly, comparison of sections through the
crural block of 2-day-old wild-type, GTF2IRD2 and TFII-Ib
transgenic pups revealed no obvious differences in muscle
histology or fiber type patterning (Fig. 2B; data not shown)
Fig. 1. Origin and evolution of the GTF2IRD2 gene. (A) Alignment (to scale) of the orthologous genomic regions of five vertebrate species based on current
genome assemblies shows strong conservation of synteny for the GTF2I gene family. The GTF2IRD2 gene is present in an identical location in the three
mammalian lineages, but not in the marsupial Monodelphis domestica. The box in the opossum genome indicates a rearrangement upstream of GTF2IRD1 that is
divergent from the main vertebrate archetype. The shaded box in the human genome indicates the approximate position of the duplicated regions associated with
the low-copy repeats (LCRs). The third human LCR, which is positioned outside the scale of the diagram, is shown as a separate inset. (B) ClustalW alignment of
GTF2IRD2 amino acid sequence from three mammalian species showing high levels of sequence conservation. Positions of the leucine zipper, repeat domains,
CHARLIE8 domain and presumptive SUMOylation sites are shown.
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suggesting that these fiber type shifts are also due to post-natal
conversion. Western blots of soleus muscle extracts from
individual GTF2IRD2 transgenic animals, probed with anti-
MyHC type I antibody, supported the immunohistochemistry
results and illustrated the degree of MyHC type I upregulation
associated with GTF2IRD2 expression (Fig. 2C).
GTF2IRD2 expression in muscle causes reduced fiber
diameter and increased fiber numbers
Apart from the fiber type shifts, analysis of body weight and
muscle histology revealed no other changes in muscle as a result
of GTF2IRD1 (Issa et al., 2006) and TFII-Ib expression. In
contrast, GTF2IRD2 led to a post-natal decline in body weight.
Longitudinal body weight data (Fig. 3A,B) showed that weight
differences were not significantly different at 2 weeks of age, but
from 4 weeks onwards, male and female transgenic mice showed
an 8–18% reduction in body weight compared with wild-type
controls. In the highest expressing GTF2IRD2 line, it was
possible to distinguish the adult transgenic animals from their
wild-type siblings by external appearance alone, based on
reduced muscle size and slow movement. Since the HSA
promoter restricts transgene expression to skeletal muscle
tissue, it is expected that this effect is attributable to loss of
muscle mass; although, an impact on muscle function that affects
movement and behavior could feed back on overall welfare. To
analyze muscle fiber size in detail, individual extensor digitorum
longus (EDL) samples were collected from GTF2IRD2
transgenic mice and wild-type controls. Transverse sections
were cut at the midpoint of the muscle to reduce the complication
of muscle orientation and depth for quantitative analysis
(Fig. 3C). Analysis of fiber diameter revealed an overall shift
Fig. 2. Transgenic expression of GTF2IRD2 and TFII-Ib in muscle tissue
causes fiber type shifts in opposing directions. (A) Whole sections through
the lower hind limbs of wild-type (WT), TFII-Ib (TFII-I), GTF2IRD2 (IRD2)
and GTF2IRD1 (IRD1) transgenic mice. The near-adjacent sections were
stained for MyHC type I (slow) and fast type MyHC IIa. The soleus muscle is
outlined in blue. T, tibia; F, fibula. (B) Whole section through the lower hind
limb of a 2-day-old GTF2IRD2 transgenic mouse stained for MyHC type I
showing normal distribution and numbers of stained and unstained muscle
fibers. Outline indicates soleus muscle. (C) Western blot of soleus muscle
protein extracts from two wild-type (WT) and two GTF2IRD2 transgenic
(TG) mice probed with the anti-MyHC type I antibody (top panel). An
identically loaded gel was stained with Coomassie Blue to show equivalent
loading (bottom panel).
Fig. 3. GTF2IRD2 transgenic mice have reduced body weight, reduced
muscle fiber size and increased fiber number. (A,B) Body weight data from
three litters of GTF2IRD2 transgenic and wild-type mice of 2–8 weeks of age
(*P,0.05, **P,0.01, NS, not significant). (C) Transverse sections of
extensor digitorum longus (EDL) muscles from a wild-type (WT) and a
GTF2IRD2 transgenic (TG) mouse stained for MyHC type I showing the
reduced average fiber diameter in the TG muscle and the increased incidence
of type I fibers. (D) Analysis of all muscle fiber diameters in transverse
sections of EDL muscle from two female transgenic (TG) and two female
wild-type (WT) mice showing the frequency of fibers falling into 5 mm bins.
(E,F) Analysis of differences in total area (E) and total fiber number (F) in
transverse sections of EDL muscles from five transgenic and five wild-type
mice show that total transverse sectional area is reduced by ,29%
(*P50.0167), whereas fiber number is increased by approximately
41% (**P50.00146).
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in the entire EDL fiber population towards decreased thickness
(Fig. 3D) and mean fiber diameter shows an approximate
reduction of 18% from 27.2 mm in the wild-type mice to
22.4 mm in the GTF2IRD2 transgenic mice. This results in a
significant reduction in mean whole muscle cross-sectional area
(Fig. 3E). However, the muscle fiber size reduction was offset to
some extent by an increase in muscle fiber number (Fig. 3F).
Qualitative examination of other muscles in the crural block
(Fig. 2A) revealed that these effects are common to all muscles
in the lower hind limb except for the soleus. Transverse sections
of dissected soleus muscles revealed no significant alteration in
the number of fibers with a mean total of 891 in the GTF2IRD2
transgenic mice compared with 888 in the wild-type mice and no
significant difference in the mean fiber diameter or the range of
sizes (n54 per genotype). However, analysis of fiber type
revealed the same large increase in MyHC type I fibers seen in
the crural sections with a variability that correlated
approximately with the level of transgene expression in each
line (data not shown).
GTF2IRD2 antagonizes the soleus fiber type shift caused
by GTF2IRD1
Since expression of human GTF2IRD1 protein in muscle leads to
an extreme fiber type shift from slow (MyHC I) to fast (MyHC
IIa) type (Issa et al., 2006) and TFII-Ib expression causes a
similar, but less extreme shift in the same direction, whereas
GTF2IRD2 causes the reverse shift from fast to slow (Fig. 2A), it
seemed likely that these proteins operate on the same mechanism,
but with antagonistic activities. To test this hypothesis in more
detail, the GTF2IRD1 transgenic mice were crossed with the
GTF2IRD2 line in order to generate double heterozygous
GTF2IRD1/Gtf2ird2 mice. Crural block sections were analyzed
for fiber type distribution using immunohistochemistry (Fig. 4A–
D). Although these soleus muscles showed irregular fiber size
and unusual fiber type patterning, it was clear that the balance of
slow and fast IIa fibers had been restored to some extent,
suggesting a degree of functional complementation (Fig. 4A–D).
In contrast, the reduction of fiber diameter in muscles outside the
soleus was even more pronounced than in the GTF2IRD2 line
alone and, unlike the GTF2IRD2 line, the soleus itself was also
subject to reductions of fiber size (data not shown).
GTF2IRD2 localizes to punctate nuclear bodies in skeletal
muscle fibers
It is assumed, based on transcript analysis, that endogenous
GTF2IRD2 protein abundance is very low (Tipney et al., 2004).
Immunofluorescent detection of the transgenic GTF2IRD2
protein was achieved using an anti-GTF2IRD2 antibody on
longitudinal muscle sections from GTF2IRD2 transgenic mice
and wild-type controls. Large and small punctate nuclear bodies
could be seen (Fig. 4E) in the GTF2IRD2 transgenic samples.
Although this antibody is known to cross-react with TFII-I (data
not shown), the wild-type control muscle samples showed no
signal (Fig. 4F) illustrating that the nuclear punctate bodies can
be entirely attributed to the transgenic GTF2IRD2 protein.
GTF2IRD2 protein localizes to punctate nuclear domains
and microtubules in cells in culture
As a means to assess the distribution of GTF2IRD2 protein in
mammalian cells, we constructed GFP-tagged and Myc-tagged
expression constructs containing the Gtf2ird2 mouse cDNA. These
constructs were transfected into several cell lines including C2C12,
COS-7, NIH3T3 and HeLa. The results were similar in all cell lines
in that GTF2IRD2 protein was found to localize to nuclear foci of
variable size and density as well as displaying cytoplasmic
localization to a cytoskeletal element suspected to be microtubules
(Fig. 5A–C). The microtubule association was confirmed using
double immunofluorescence analysis with transfected GFP–
GTF2IRD2 and an anti-a-tubulin antibody during (Fig. 5D) and
after (Fig. 5E) nocodazole treatment, which blocks microtubule
polymerization. Cytoplasmic GFP–GTF2IRD2 colocalized with
fluorescently labeled a-tubulin-containing microtubules, but during
nocodazole treatment, the cytoplasmic GFP–GTF2IRD2 was
scattered in vesicular-like structures (Fig. 5D).
In the nucleus, GFP–GTF2IRD2 and Myc–GTF2IRD2
localized to foci of two distinct size categories; large spherical
inclusions and smaller, more numerous nuclear bodies. To
identify the nature of the small nuclear bodies, GFP–GTF2IRD2-
transfected cells were used in colocalization studies using
antibodies against a variety of known punctate nuclear proteins
(Fig. 6A–D). However, none of these proteins including SC35
(nuclear speckles/splicing bodies), Coilin (Cajal bodies), Pml
(Pml bodies), Sam68 [SAM68 nuclear body (SNB)], Bmi1
(polycomb bodies) and Sp1 (OPT domains – data not shown)
were found to colocalize consistently with GFP–GTF2IRD2. The
same was also true of the large nuclear bodies. In order to test
Fig. 4. GTF2IRD1 and GTF2IRD2 antagonism in soleus muscles and
distribution of GTF2IRD2 transgenic protein in muscle nuclei.
(A–D) Detail of soleus muscles in whole hind limb transverse sections from
two mice carrying both the GTF2IRD1 and the Gtf2ird2 transgene.
(A,C) Sections stained with anti-MyHC I; (B,D) near-adjacent sections
stained with anti-MyHC IIa. (E,F) High power images of DAPI-stained nuclei
from longitudinal muscle sections treated with anti-GTF2IRD2 antibodies and
secondary immunofluorescent detection. GTF2IRD2 protein (green foci) is
detectable in the GTF2IRD2 TG section (E) but not in the wild-type control
section (F).
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whether the GTF2IRD2 foci associate with inactive or active
chromatin regions, GFP–GTF2IRD2 distribution was assessed in
association with DAPI-stained chromatin using confocal imaging
(Fig. 6E,F), which suggested some exclusion of GFP–GTF2IRD2
from dense heterochromatin. These results were explored further
by examining the distribution of GFP–GTF2IRD2 in relation to
active chromatin marked by trimethylated histone H3 lysine 4
(Fig. 6G) and inactive chromatin marked by trimethylated
histone H3 lysine 9 (Fig. 6H). These data indicated that while
the GFP–GTF2IRD2 foci appear to be excluded from regions of
inactive heterochromatin, there is not a strong association with
active chromatin either and it is unclear whether chromatin
tethering plays any role in GTF2IRD2 distribution. However, by
dividing the mouse Gtf2ird2 cDNA into two halves at the
junction formed by the beginning of the CHARLIE8 domain and
cloning these into GFP expression plasmids, it was possible to
examine the behavior of the N-terminal (aa1–411) and C-
terminal (aa412–936) halves separately. The GFP–N-terminal
domain was generally distributed in a broad cytoplasmic pattern
(Fig. 6I) supporting the view that this region lacks a nuclear
localization signal. When the GFP–C-terminal half was
transfected into cells, all of the protein was localized
exclusively to a small number of large spherical nuclear bodies
(Fig. 6J) and none of the small nuclear bodies or microtubule
associations were seen, thus suggesting that the large nuclear
bodies can be attributed to associations formed by the
CHARLIE8 domain alone and that both regions of the protein
work in conjunction to create the association with microtubules
and the small nuclear bodies.
Recombinant GTF2IRD1 and TFII-I colocalize with the
GTF2IRD2 punctate nuclear domains located at the
nuclear periphery
Confocal analysis of the distribution of Myc and GFP-tagged
GTF2IRD2 protein in COS-7 cells revealed that the punctate
nuclear domains were preferentially located at the periphery of
the nucleus (Fig. 7A). Analysis of the location of the endogenous
nuclear pore complexes (NPCs) revealed that there was no
overlap in location and the GTF2IRD2 bodies occupied a slightly
more interior zone than the NPCs (Fig. 7B–D). Analysis of the
relative location of the lamin-associated protein LAP2B
supported this conclusion (data not shown). Since the
functional evidence suggests that GTF2IRD1, TFII-I and
GTF2IRD2 act on a common mechanism in muscle tissue, we
sought to examine whether all three family members were
capable of colocalization in cultured cells. Firstly, the basal
distribution of Myc and GFP-tagged GTF2IRD1 and TFII-Ib
proteins were examined using confocal microscopy, which
revealed a similar distribution. Fluorescence was detected
throughout the nucleus in a broad patchy pattern, excluded
from nucleoli, but otherwise evenly distributed with no evidence
of a peripheral bias (Fig. 7E,F). By contrast, when GFP-tagged
GTF2IRD1 and TFII-I were co-expressed with Myc-GTF2IRD2,
it became obvious that these proteins had adopted the punctate
nuclear pattern and both colocalized extensively with GTF2IRD2
(Fig. 7G–L). This colocalization required the presence of the N-
terminal half of the protein as expression of the GFP–C-terminal
half with Myc-tagged GTF2IRD1 resulted in separate distribution
patterns (data not shown).
Fig. 5. GTF2IRD2 localizes to punctate nuclear domains
and microtubules. (A–C) GFP-tagged GTF2IRD2 protein
localizes to cytoplasmic microtubules and punctate nuclear
bodies in NIH 3T3 cells (A) and COS-7 cells (B). (C) High
power image of a DAPI-stained nucleus showing that the
GFP–GTF2IRD2 bodies (green) can form both large spheres
and smaller more numerous speckles. (D) GFP–GTF2IRD2-
expressing COS-7 cells treated for 2 hours with nocodazole
show disruption of the tubulin polymers and disruption of the
associated GFP–GTF2IRD2, whereas the punctate nuclear
bodies are unaffected. (E) Withdrawal of nocodazole for
1 hour permits re-formation of the tubulin cytoskeleton and re-
association of GFP–GTF2IRD2 with the microtubules.
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GTF2IRD2 interacts directly with GTF2IRD1 and TFII-I
Colocalization of these three protein family members could be
due to binding of the proteins to common protein complexes in
the cell or it could indicate direct interaction between these
proteins. Reciprocal co-immunoprecipitation experiments
revealed that recombinant GTF2IRD2, GTF2IRD1 and TFII-I
are all capable of cross interaction. The highest affinity found
was between GTF2IRD2 and itself followed by TFII-I and
GTF2IRD1 in decreasing order of affinity (Fig. 8).
Discussion
This study provides the first functional analysis of GTF2IRD2,
which is of interest from two different perspectives. Firstly, this
protein is the third member of a small family that are intimately
concerned with the genetic cause of WBS (Antonell et al., 2010).
Understanding the function of these genes will provide an
essential insight into the cause of the disease and has the potential
for insights into genetic mechanisms that underpin features of
WBS patients; inroads into the function in one tissue informs on
Fig. 6. GTF2IRD2 nuclear bodies do not associate with recognized
nuclear foci or chromatin domains and the large spherical inclusions are
caused by the CHARLIE8 region. Immunofluorescence detection of GFP-
tagged GTF2IRD2 in transfected HeLa and COS-7 cells with various
endogenous nuclear foci (red). (A–D) GTF2IRD2 bodies do not show strong
associations with SC35 nuclear speckles in COS-7 (A), coilin-containing
Cajal bodies in HeLa (B), Pml bodies in HeLa (C) or Bmi1-identified
polycomb bodies in HeLa (D). (E) Confocal image of a DAPI-stained nucleus
and (F) the same image overlaid with the GFP–GTF2IRD2 distribution.
(G) COS-7 nucleus showing the distribution of GFP–GTF2IRD2 relative to
trimethylated H3K4 active chromatin marks. (H) COS-7 nucleus showing
GFP–GTF2IRD2 and trimethylated H3K9 indicating GFP–GTF2IRD2 is
largely excluded from inactive heterochromatic regions. (I,J) Schematics of
GFP-tagged protein constructs containing the N-terminal or C-terminal halves
of GTF2IRD2 with the corresponding cellular distribution shown beneath.
(I) GFP–N-terminal GTF2IRD2 localizes to the cytoplasm in a diffuse
perinuclear pattern. (J) GFP–C-terminal GTF2IRD2 localizes exclusively to a
small number of large round nuclear inclusions.
Fig. 7. GTF2IRD2 localizes peripherally in the nucleus and influences
the subnuclear distribution of GTF2IRD1 and TFII-Ib. (A) A series of
confocal z-sections through the same nucleus showing the peripheral
distribution of GFP-GTF2IRD2. (B) Nucleus showing detection of
endogenous nuclear pore complex (NPC). (C) Detection of NPC (red) and
GFP–GTF2IRD2 (green) showing a lack of colocalization. (D) Higher power
image from C showing how the GFP–GTF2IRD2 sits inside the plane of the
NPCs. (E,F) Series of confocal z-sections through two nuclei shows the
distribution of (E) GFP–GTF2IRD1 and (F) GFP–TFII-I. (G–I) Detection of
Myc–GTF2IRD2 (G) by immunofluorescence and fluorescent GFP–
GTF2IRD1 (H). The overlaid image (I) shows extensive colocalization of the
two proteins in the punctate pattern typical of GTF2IRD2. (J–L) Similarly,
detection of Myc–GTF2IRD2 (J) and fluorescent GFP–TFII-I (K) also shows
extensive colocalization in the typical punctate pattern (L).
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mechanism in other organs. Secondly, this protein is encoded by
a gene that belongs to a group of functional human genes that
have been derived from the random insertion of mobile element
sequences into the genome and the exploitation of those
sequences for functional purposes (Britten, 2004). It is
interesting to consider how this exploitation has evolved and
what properties are bestowed by the sequence derived from these
mobile elements.
Structure and evolution of GTF2IRD2
Previous analysis of GTF2IRD2 sequence indicated that it is an
evolutionary derivative of the transcriptional regulator TFII-I
(Hinsley et al., 2004; Makeyev et al., 2004; Tipney et al., 2004).
However, during divergence from the common ancestor,
GTF2IRD2 has undergone some significant rearrangements that
preserve some of the features of TFII-I in the N-terminal half,
while the C-terminal half has been lost and replaced by the in-
frame insertion of a CHARLIE8 transposon. Sequence evidence
suggests that subsequent to the insertion, both halves of the
protein have continued to diverge from their original forms. At
some point the sequence stabilized, presumably as a result of
evolved functional constraints, and the orthologs of GTF2IRD2
are now highly conserved in all of the eutherian mammal lineages
for which good sequence is available.
It has been pointed out that the two RDs that remain in
GTF2IRD2 compared to the six originally present in TFII-I, are
most closely related to RD1 and RD6 of TFII-I (Makeyev et al.,
2004). This means that the RD2 of TFII-I and its adjacent basic
region, which is thought to represent the principal site of TFII-I
DNA binding (Cheriyath and Roy, 2001; Roy, 2001), is missing in
GTF2IRD2. In addition, a PredictNLS survey of the entire
sequence indicates no evidence of a recognizable nuclear
localization signal (Hinsley et al., 2004). However, the N-
terminal leucine zipper and the sequence surrounding it in TFII-I
is highly conserved in GTF2IRD2, as is the sequence shared in
RD1 of both proteins. This would suggest that the dimerization
properties, which have been shown to be mediated via the leucine
zipper region and RD1 (also TFII-I RD2) working together to form
an N-terminal dimerization domain (Cheriyath and Roy, 2001)
have been highly conserved in GTF2IRD2. Other similarities
include the presence of well-conserved SUMOylation motifs in
both proteins and analysis of mass-purified, SUMO-ligated
proteins has shown that TFII-I and GTF2IRD2 are indeed
SUMOylation targets (Zhao et al., 2004; Ganesan et al., 2007).
However, it is completely unknown what functions are brought by
the addition of the CHARLIE8 sequences. Although sequence has
diverged from the original transposon from which this region is
derived, several recognizable transposase functional domains are
identifiable within the sequence (Tipney et al., 2004) and it is
likely that these have bestowed novel characteristics on this
protein.
Subcellular localization of GTF2IRD2, GTF2IRD1 and TFII-I
The localization of recombinant GTF2IRD2 was found to differ
significantly from the localization of TFII-Ib and GTF2IRD1
which are broadly distributed throughout the nuclear
compartment. GTF2IRD2 was found to be located on
microtubules in the cytoplasm and in two types of distinct
nuclear foci. The large spherical nuclear foci were shown to be
entirely attributable to the CHARLIE8 region as a GFP-tagged
CHARLIE8 fusion protein located exclusively to these domains.
Analysis of the corresponding GFP-tagged N-terminal half
revealed a loose perinuclear cytoplasmic location, which
indicates that the N-terminal half lacks a nuclear localization
signal (NLS) and it must be concluded that the NLS functions are
now provided by the CHARLIE8 domain. Subcellular
localization of the hAT transposases is poorly understood
except for work showing that basic amino acid regions
interspersed with the BED DNA-binding domain are
responsible for nuclear localization (Michel and Atkinson,
2003). There is no current evidence that indicates hAT
transposases adopt a punctate nuclear pattern or microtubule
associations. Together these findings indicate that the unique
pattern of GTF2IRD2 localization requires both the CHARLIE8
domain and the TFII-I N-terminal region working in unison and
has evolved separately as part of a newly acquired evolutionary
function. However, confirmation of these localization patterns
will have to await the development of antibodies that are specific
and sensitive enough to detect endogenous GTF2IRD2.
Fig. 8. GTF2IRD2 interacts with itself, TFII-I and GTF2IRD1 in
decreasing order of affinity. (A) Western blots of protein extracts from
HEK293 cells transfected with combinations of constructs encoding GFP-
tagged and Myc-tagged recombinant proteins before (INPUT) and after
(MYC IP) immunoprecipitation using anti-Myc antibody to enrich for Myc-
tagged protein complexes. The nature of the probe antibody is shown on the
right. Band intensity indicates that GTF2IRD2 has a strong affinity for itself,
weaker for TFII-I and weaker still for GTF2IRD1; GTF2IRD1 and TFII-Ib
also co-immunoprecipitate together. (B) Western blot showing a reciprocal
immunoprecipitation experiment to that in A, using GFP–GTF2IRD2 to
precipitate the protein complexes. This analysis also shows a decreasing
affinity of GTF2IRD2 for itself, TFII-Ib and GTF2IRD1 as above. Negative
control immunoprecipitations using GFP only or Myc-tagged SETD7 showed
no co-immunoprecipitation of target proteins (data not shown).
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Confocal analysis of GTF2IRD2 localization revealed a
predominance of peripheral localization, but the position does
not coincide with the NPC and is slightly internal to the level of
the nuclear lamina when compared to the localization of LAP2B
(data not shown). No overlap with any other nuclear foci could be
identified and no strong association was found with domains of
inactive or active chromatin, although GTF2IRD2 was generally
excluded from dense regions of heterochromatin. In contrast,
when GTF2IRD1 and TFII-Ib were expressed individually in
COS-7 cells, the proteins were distributed throughout the interior
of the nucleus except for exclusion from nucleoli. When
GTF2IRD1 and TFII-Ib were co-expressed with GTF2IRD2,
they adopted the punctate pattern typical of GTF2IRD2. Based on
the ability of these proteins to interact directly in co-
immunoprecipitation experiments and the high conservation of
the N-terminal region, which is involved in dimerization, we
propose that the evolved function of GTF2IRD2 is to sequester
TFII-I and GTF2IRD1 proteins to regions of the nucleus that
prevent their normal functions as transcriptional regulators. It is
possible that some sequestration to microtubules also occurs, but
no clear evidence of this in co-expression studies could be seen.
Under this hypothesis, the ability to interact with the GTF2I
family of proteins has been strongly retained in the leucine zipper
and RD1 surfaces, whereas the combined effect of the
CHARLIE8 and the N-terminal TFII-I region has led to an
entirely new pattern of protein localization in the cell. The
resulting consequence is an ability to modulate GTF2IRD1 and
TFII-I function by protein sequestration.
For this sequestration model to be effective, it requires that the
levels of GTF2IRD2 in the nucleus are sufficient to have an impact
on the levels of TFII-I or GTF2IRD1 proteins. Gtf2ird2 transcript
levels are, generally speaking, low (Tipney et al., 2004), as are
Gtf2ird1 transcript levels (O’Mahoney et al., 1998; Calvo et al.,
2001), whereas Gtf2i transcripts are more readily detectable (Roy
et al., 1997; Danoff et al., 2004). However, the Gtf2i gene
generates four different TFII-I protein isoforms that vary in their
properties for basal nuclear occupancy or nuclear/cytoplasmic
shuttling (Hakre et al., 2006). Antibody detection of total TFII-I
protein in the mouse brain suggests that most TFII-I exists in the
cytoplasm (Danoff et al., 2004) where it is presumably tethered by
p190RhoGAP (Jiang et al., 2005), Bruton’s tyrosine kinase
(Sacrista´n et al., 2004) or by interactions with PLC-c (Caraveo
et al., 2006). We suggest that GTF2IRD2 sequestration would only
be active against TFII-I or GTF2IRD1 proteins that enter the
nucleus, which, in the case of the TFII-I isoforms, is largely
dependent on the status of cell signaling (Roy, 2012). Therefore
the relative stoichiometry of GTF2IRD2 and TFII-I isoforms in the
nucleus is unstable and would be difficult to determine.
Functional analysis of GTF2IRD2 and TFII-Ib in the muscle
transgenic model system
Analysis of TFII-I in the muscle transgenic system was
conducted at the same time as GTF2IRD2 in order to be able
to compare GTF2IRD2 with its closest homolog. The b-isoform
was selected because it is the predominant isoform expressed in
mouse tissues (Cheriyath and Roy, 2000) and it is constitutively
nuclear under basal conditions where it is thought to act as a mild
repressor of target genes via recruitment of histone deacetylases
(HDACs) to sites of DNA binding (Hakre et al., 2006).
Analysis of muscle fiber type in TFII-Ib transgenic mice
supports previous reports of TFII-Ib as a mild repressor of gene
targets and the notion that TFII-I and GTF2IRD1 are capable of
regulating the same set of target genes (Tantin et al., 2004)
because an almost identical slow to fast post-natal conversion of
fiber type was observed in the TFII-Ib mice compared with the
original GTF2IRD1 transgenic mice (Issa et al., 2006). However,
the magnitude of the shift was smaller despite estimated higher
levels of transgenic Gtf2ib mRNA abundance (data not shown).
In contrast, the GTF2IRD2 transgenic mice showed a
consistent and profound post-natal conversion in the opposite
direction from fast to slow. This is very apparent in the soleus
muscle and to a lesser degree in the surrounding core limb
muscles. However, unlike the soleus muscle and unlike the TFII-
Ib and GTF2IRD1 models, the surrounding muscles of adult
GTF2IRD2 transgenic mice also have much thinner muscle
fibers. Since patterning and muscle fiber appearance was normal
at post-natal day 2, the thinness of the fibers could be caused by
an attenuation of post-natal maturation hypertrophy. There is also
a significant increase in the number of muscle fibers, which could
represent a compensatory mechanism to combat the significant
reduction in fiber size. These data indicate that the effects of
GTF2IRD2 differ according to cell context and may reflect
underlying molecular differences in epigenetic programming or
the profile of transcriptional regulators present.
Based on the analysis of GTF2IRD2 behavior in cultured cells,
the simplest mechanism to explain the fiber type conversion is to
propose that sequestration of GTF2IRD1 and TFII-Ib proteins leads
to inactivation of their usual functions resulting in an antagonistic
release from their repressive effects. This model predicts that co-
expression of GTF2IRD2 and TFII-Ib or GTF2IRD1 transgenes
would set up an antagonistic balance in which a more even fiber
type distribution has been restored. By interbreeding of GTF2IRD1
and GTF2IRD2 transgenic mice it was possible to show that this
conclusion is correct. However, fiber size reduction in the
surrounding muscle fibers was even more pronounced than in
GTF2IRD2 transgenics alone, suggesting that the fiber size
reduction mechanism does not work in this fashion. This model
also predicts that endogenous GTF2IRD1 and/or TFII-I play a role
in the maintenance of muscle fiber type as it is proposed that
GTF2IRD2 only exerts its effects indirectly via the attenuation of
these proteins. Gtf2ird1 is expressed strongly during skeletal
muscle development, but is downregulated in mature muscle
(Palmer et al., 2007). Studies on Gtf2ird1 knockout mice (Palmer
et al., 2010; Howard et al., 2012) have so far failed to reveal fiber
type changes, which may reflect very low levels of adult
expression. By contrast, Gtf2i mRNA is relatively abundant in
adult skeletal muscle tissue (Roy et al., 1997) and therefore TFII-I
is the best candidate for such a role. Homozygous Gtf2i mutations
cause embryonic lethality (Enkhmandakh et al., 2009) so proper
analysis of TFII-I function in muscle tissue will have to await the
development of tissue-specific conditional knockout mice.
Materials and Methods
Bioinformatics
Data on conservation of synteny surrounding the GTF2I family of genes across
vertebrate species, the relative chromosomal positions and the amino acid
sequence of the three mammalian species of GTF2IRD2 was accessed via the
Ensembl database (http://www.ensembl.org/index.html). Amino acid sequence
was aligned using ClustalW (Thompson et al., 1994).
Plasmid constructs
Based on sequence information accessed via the Ensembl database, cDNA
sequences corresponding to the open reading frame (ORF) of human GTF2IRD1
(1a1 isoform), mouse Gtf2ird2 and mouse Gtf2i (b-isoform) were amplified from
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human and mouse cell lines by RT-PCR and cloned into the pEGFP-C1 (Clontech)
mammalian GFP vector. The pEGFP-GTF2IRD2 and pEGFP-TFII-Ib vectors were
also modified by removal of the EGFP cDNA and re-ligation of a linker containing
the sequence encoding the c-Myc epitope tag. C-terminal and N-terminal portions
of the mouse Gtf2ird2 gene were amplified and cloned into pEGFP-C1 using the
same strategy.
Gtf2ird2 and Gtf2i ORFs were ligated into the same plasmid construct used to
generate the GTF2IRD1 transgenic line (Issa et al., 2006), which ensures skeletal-
muscle-specific expression driven by the human skeletal actin gene (ACTA1).
Cell lines and immunofluorescence
For examination of subcellular localization, NIH3T3, COS-7 and HeLa cells were
grown on glass coverslips using standard culture conditions and expression
plasmids were transfected using Lipofectamine LTX and PLUS reagent
(Invitrogen) according to manufacturer’s instructions. Cells were fixed and
permeabilized in 4% paraformaldehyde in PBS followed by ice-cold methanol, or
by a combined 4% paraformaldehyde/0.125% Triton X-100 in PBS incubation.
Disruption of microtubules was achieved by addition of nocodazole to the culture
medium (dissolved in DMSO) to a final concentration of 1 mM for 2 hours.
Recovery following nocodazole treatment involved replacement with fresh culture
medium for 1 hour. Antibodies used in immunofluorescence to detect the Myc-tag
and endogenous proteins include: anti-Myc (monoclonal 9E10, Sigma), anti-a-
tubulin (monoclonal DM1A, Sigma), anti-SC35 (monoclonal Abcam ab11826),
anti-coilin (monoclonal Abcam ab11822), anti-PML (rabbit polyclonal Abcam
ab53773), anti-SAM68 (rabbit polyclonal Abcam ab26803), anti-BMI1 (rabbit
polyclonal Abcam ab38295), anti-nuclear pore complex proteins (Mab414 Abcam
ab24609), anti-trimethyl-histone H3K4 (monoclonal Abcam ab12209) and anti-
trimethyl-histone H3K9 (polyclonal Abcam ab8898). The fluorescent secondary
antibody was Alexa Fluor 555 (Invitrogen). Fixed cells were blocked in 10%
normal goat serum (Vector) in PBS and incubated with antibodies and washed
according to standard methods. Nuclei were stained with DAPI in PBS (0.1 mg/
ml) before mounting in immu-mount (Thermo-Shandon). Cells were imaged with
conventional epifluorescence using a Zeiss Axioskop 40 with AxioCam MRC and
Axiovision software or with an Olympus Fluoview FV1000 confocal microscope
with Fluoview software (V2.0).
Immunohistochemistry and histology
Muscle tissue was cryostat sectioned and stained for the myosin heavy chain
(MyHC) subtypes I and IIA as described previously (Issa et al., 2006). Detection of
transgenic GTF2IRD2 expressed in muscle tissue was achieved using the anti-
GTF2IRD2 antibody (Abnova BO1P polyclonal) followed by Alexa Fluor 488
(Invitrogen). Fiber diameters and fiber counts were quantified from images of
muscle sections using ImageJ software (http://rsbweb.nih.gov/ij/). All statistical
comparisons were made using a one-tailed Student’s t-test.
Western blotting and co-immunoprecipitation
Myosin heavy chain type I (b slow) was extracted for quantification using the
procedure described by Hoh et al. (1976). Proteins were separated by
electrophoresis on an 8% SDS-PAGE gel, blotted onto Immobilon-P PVDF
membrane (Millipore) and MyHCI was detected using a BA-F8 monoclonal
antibody (Borrione et al., 1988), followed by an anti-mouse Ig-HRP-conjugated
secondary antibody (Santa Cruz Biotechnology) and detection with Western
Lightning ECL reagents (PerkinElmer).
Co-immunoprecipitation of the GTF2I family of proteins was achieved by co-
transfection of HEK293 cells with 5 mg of each plasmid (except in the case of
EGFP-transfected controls where only 100 ng was used) using a standard calcium
phosphate precipitation protocol, followed by collection in lysis buffer [phosphate-
buffered saline, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF and
16Complete Protease Inhibitor Cocktail (Roche)]. Cells were frozen on dry ice,
rapidly thawed and forced through a 0.6 mm syringe ten times to lyse the cells.
Immunoprecipitation was performed using Protein-G–Sepharose-4 Fast Flow
beads (GE Healthcare) and anti-Myc or anti-GFP (rabbit polyclonal, Abcam
ab290) antibodies.
Immunoprecipitated proteins were separated by electrophoresis on a 10% SDS-
PAGE gel, blotted onto Immobilon-P PVDF membrane and probed with anti-Myc
or anti-GFP antibodies followed by either anti-mouse or anti-rabbit Ig-HRP-
conjugated secondary antibody (Santa Cruz Biotechnology) and detection with
ECL reagents.
Transgenic mice
Transgene constructs were isolated from the vector and microinjected into
fertilized oocytes of C57BL/66DBA/2J F1 mice to establish the transgenic lines
expressing GTF2IRD2 [B6D2-Tg(ACTA1-Gtf2ird2)30Hrd] and TFII-Ib [B6D2-
Tg(ACTA1-Gtf2ib)29Hrd] on an isogenic background to the GTF2IRD1 line (Issa
et al., 2006) [B6D2-Tg(ACTA1-GTF2IRD1.1a1)22Hrd] for comparative purposes.
Transgene copy number was estimated via Southern blot analysis and transgene
expression was measured by northern blot as described elsewhere (Issa et al.,
2006).
Acknowledgements
The authors would like to thank Kim Guven for making the
transgenic constructs, Josephine Joya for generating the transgenic
founder mice, Dr Geraldine O’Neil for assistance with the tubulin
experiments, Axel Neumann for the Pml antibody and nuclear
microscopy work and Archa Fox for advice on nuclear speckle
patterns. The authors also thank Paulina Carmona-Mora and
Anthony Kee for critical review of the manuscript.
Funding
This work was supported by the Australian Research Council [grant
number DP0984430 to S.J.P and E.C.H.]; the Australian National
Health and Medical Research Council [grant number 423401 to
S.J.P. and E.C.H.]; and J.W. held a University of New South Wales
Postgraduate Award.
References
Antonell, A., Del Campo, M., Magano, L. F., Kaufmann, L., de la Iglesia, J. M.,
Gallastegui, F., Flores, R., Schweigmann, U., Fauth, C., Kotzot, D. et al. (2010).
Partial 7q11.23 deletions further implicate GTF2I and GTF2IRD1 as the main genes
responsible for the Williams-Beuren syndrome neurocognitive profile. J. Med. Genet.
47, 312-320.
Bayarsaihan, D. and Ruddle, F. H. (2000). Isolation and characterization of BEN, a
member of the TFII-I family of DNA-binding proteins containing distinct helix-loop-
helix domains. Proc. Natl. Acad. Sci. USA 97, 7342-7347.
Borrione, A. C., Zanellato, A. M., Saggin, L., Mazzoli, M., Azzarello, G. and
Sartore, S. (1988). Neonatal myosin heavy chains are not expressed in Ni-induced rat
rhabdomyosarcoma. Differentiation 38, 49-59.
Brennan, K. J. and Hardeman, E. C. (1993). Quantitative analysis of the human alpha-
skeletal actin gene in transgenic mice. J. Biol. Chem. 268, 719-725.
Britten, R. J. (2004). Coding sequences of functioning human genes derived entirely
from mobile element sequences. Proc. Natl. Acad. Sci. USA 101, 16825-16830.
Calvo, S., Vullhorst, D., Venepally, P., Cheng, J., Karavanova, I. and Buonanno, A.
(2001). Molecular dissection of DNA sequences and factors involved in slow muscle-
specific transcription. Mol. Cell. Biol. 21, 8490-8503.
Caraveo, G., van Rossum, D. B., Patterson, R. L., Snyder, S. H. and Desiderio, S.
(2006). Action of TFII-I outside the nucleus as an inhibitor of agonist-induced
calcium entry. Science 314, 122-125.
Casteel, D. E., Zhuang, S., Gudi, T., Tang, J., Vuica, M., Desiderio, S. and Pilz, R. B.
(2002). cGMP-dependent protein kinase I beta physically and functionally interacts
with the transcriptional regulator TFII-I. J. Biol. Chem. 277, 32003-32014.
Cheriyath, V. and Roy, A. L. (2000). Alternatively spliced isoforms of TFII-I. Complex
formation, nuclear translocation, and differential gene regulation. J. Biol. Chem. 275,
26300-26308.
Cheriyath, V. and Roy, A. L. (2001). Structure-function analysis of TFII-I. Roles of the
N-terminal end, basic region, and I-repeats. J. Biol. Chem. 276, 8377-8383.
Danoff, S. K., Taylor, H. E., Blackshaw, S. and Desiderio, S. (2004). TFII-I, a
candidate gene for Williams syndrome cognitive profile: parallels between regional
expression in mouse brain and human phenotype. Neuroscience 123, 931-938.
Doi-Katayama, Y., Hayashi, F., Inoue, M., Yabuki, T., Aoki, M., Seki, E., Matsuda,
T., Kigawa, T., Yoshida, M., Shirouzu, M. et al. (2007). Solution structure of the
general transcription factor 2I domain in mouse TFII-I protein. Protein Sci. 16, 1788-
1792.
Enkhmandakh, B., Makeyev, A. V., Erdenechimeg, L., Ruddle, F. H., Chimge,
N. O., Tussie-Luna, M. I., Roy, A. L. and Bayarsaihan, D. (2009). Essential
functions of the Williams-Beuren syndrome-associated TFII-I genes in embryonic
development. Proc. Natl. Acad. Sci. USA 106, 181-186.
Ganesan, A. K., Kho, Y., Kim, S. C., Chen, Y., Zhao, Y. and White, M. A. (2007).
Broad spectrum identification of SUMO substrates in melanoma cells. Proteomics 7,
2216-2221.
Hakre, S., Tussie-Luna, M. I., Ashworth, T., Novina, C. D., Settleman, J., Sharp,
P. A. and Roy, A. L. (2006). Opposing functions of TFII-I spliced isoforms in growth
factor-induced gene expression. Mol. Cell 24, 301-308.
Hinsley, T. A., Cunliffe, P., Tipney, H. J., Brass, A. and Tassabehji, M. (2004).
Comparison of TFII-I gene family members deleted in Williams-Beuren syndrome.
Protein Sci. 13, 2588-2599.
Hoh, J. Y., McGrath, P. A. and White, R. I. (1976). Electrophoretic analysis of
multiple forms of myosin in fast-twitch and slow-twitch muscles of the chick.
Biochem. J. 157, 87-95.
Howard, M. L., Palmer, S. J., Taylor, K. M., Arthurson, G. J., Spitzer, M. W., Du,
X., Pang, T. Y., Renoir, T., Hardeman, E. C. and Hannan, A. J. (2012). Mutation
of Gtf2ird1 from the Williams-Beuren syndrome critical region results in facial
dysplasia, motor dysfunction, and altered vocalisations. Neurobiol. Dis. 45, 913-922.
GTF2IRD2 antagonizes its family members 5049
J
o
u
rn
a
l
o
f
C
e
ll
S
c
ie
n
c
e
Issa, L. L., Palmer, S. J., Guven, K. L., Santucci, N., Hodgson, V. R., Popovic, K.,
Joya, J. E. and Hardeman, E. C. (2006). MusTRD can regulate postnatal fiber-
specific expression. Dev. Biol. 293, 104-115.
Jiang, W., Sordella, R., Chen, G. C., Hakre, S., Roy, A. L. and Settleman, J. (2005).
An FF domain-dependent protein interaction mediates a signaling pathway for growth
factor-induced gene expression. Mol. Cell 17, 23-35.
Kim, D. W., Cheriyath, V., Roy, A. L. and Cochran, B. H. (1998). TFII-I enhances
activation of the c-fos promoter through interactions with upstream elements. Mol.
Cell. Biol. 18, 3310-3320.
Lucena, J., Pezzi, S., Aso, E., Valero, M. C., Carreiro, C., Dubus, P., Sampaio, A.,
Segura, M., Barthelemy, I., Zindel, M. Y. et al. (2010). Essential role of the N-
terminal region of TFII-I in viability and behavior. BMC Med. Genet. 11, doi:
10.1186/1471-2350-11-61.
Makeyev, A. V., Erdenechimeg, L., Mungunsukh, O., Roth, J. J., Enkhmandakh, B.,
Ruddle, F. H. and Bayarsaihan, D. (2004). GTF2IRD2 is located in the Williams-
Beuren syndrome critical region 7q11.23 and encodes a protein with two TFII-I-like
helix-loop-helix repeats. Proc. Natl. Acad. Sci. USA 101, 11052-11057.
Manzano-Winkler, B., Novina, C. D. and Roy, A. L. (1996). Additions and
Corrections to TFII-I is required for transcription of the naturally TATA-less but
initiator-containing Vbeta promoter. J. Biol. Chem. 271, 16982.
Michel, K. and Atkinson, P. W. (2003). Nuclear localization of the Hermes transposase
depends on basic amino acid residues at the N-terminus of the protein. J. Cell.
Biochem. 89, 778-790.
Morris, C. A. and Mervis, C. B. (2000). Williams syndrome and related disorders.
Annu. Rev. Genomics Hum. Genet. 1, 461-484.
Novina, C. D., Kumar, S., Bajpai, U., Cheriyath, V., Zhang, K., Pillai, S., Wortis, H.
H. and Roy, A. L. (1999). Regulation of nuclear localization and transcriptional
activity of TFII-I by Bruton’s tyrosine kinase. Mol. Cell. Biol. 19, 5014-5024.
O’Mahoney, J. V., Guven, K. L., Lin, J., Joya, J. E., Robinson, C. S., Wade, R. P.
and Hardeman, E. C. (1998). Identification of a novel slow-muscle-fiber enhancer
binding protein, MusTRD1. Mol. Cell. Biol. 18, 6641-6652.
Osborne, L. R. and Mervis, C. B. (2007). Rearrangements of the Williams-Beuren
syndrome locus: molecular basis and implications for speech and language
development. Expert Rev. Mol. Med. 9, 1-16.
Palmer, S. J., Tay, E. S., Santucci, N., Cuc Bach, T. T., Hook, J., Lemckert, F. A.,
Jamieson, R. V., Gunnning, P. W. and Hardeman, E. C. (2007). Expression of
Gtf2ird1, the Williams syndrome-associated gene, during mouse development. Gene
Expr. Patterns 7, 396-404.
Palmer, S. J., Santucci, N., Widagdo, J., Bontempo, S. J., Taylor, K. M., Tay, E. S.,
Hook, J., Lemckert, F., Gunning, P. W. and Hardeman, E. C. (2010). Negative
autoregulation of GTF2IRD1 in Williams-Beuren syndrome via a novel DNA binding
mechanism. J. Biol. Chem. 285, 4715-4724.
Polly, P., Haddadi, L. M., Issa, L. L., Subramaniam, N., Palmer, S. J., Tay, E. S. and
Hardeman, E. C. (2003). hMusTRD1alpha1 represses MEF2 activation of the
troponin I slow enhancer. J. Biol. Chem. 278, 36603-36610.
Ren, X., Siegel, R., Kim, U. and Roeder, R. G. (2011). Direct interactions of OCA-B
and TFII-I regulate immunoglobulin heavy-chain gene transcription by facilitating
enhancer-promoter communication. Mol. Cell 42, 342-355.
Ring, C., Ogata, S., Meek, L., Song, J., Ohta, T., Miyazono, K. and Cho, K. W.
(2002). The role of a Williams-Beuren syndrome-associated helix-loop-helix domain-
containing transcription factor in activin/nodal signaling. Genes Dev. 16, 820-835.
Roy, A. L. (2001). Biochemistry and biology of the inducible multifunctional
transcription factor TFII-I. Gene 274, 1-13.
Roy, A. L. (2006). Transcription factor TFII-I conducts a cytoplasmic orchestra. ACS
Chem. Biol. 1, 619-622.
Roy, A. L. (2007). Signal-induced functions of the transcription factor TFII-I. Biochim.
Biophys. Acta 1769, 613-621.
Roy, A. L. (2012). Biochemistry and biology of the inducible multifunctional
transcription factor TFII-I: 10 years later. Gene 492, 32-41.
Roy, A. L., Carruthers, C., Gutjahr, T. and Roeder, R. G. (1993). Direct role for Myc
in transcription initiation mediated by interactions with TFII-I. Nature 365, 359-361.
Roy, A. L., Du, H., Gregor, P. D., Novina, C. D., Martinez, E. and Roeder, R. G.
(1997). Cloning of an inr- and E-box-binding protein, TFII-I, that interacts physically
and functionally with USF1. EMBO J. 16, 7091-7104.
Rubin, E., Lithwick, G. and Levy, A. A. (2001). Structure and evolution of the hAT
transposon superfamily. Genetics 158, 949-957.
Sacrista´n, C., Tussie´-Luna, M. I., Logan, S. M. and Roy, A. L. (2004). Mechanism of
Bruton’s tyrosine kinase-mediated recruitment and regulation of TFII-I. J. Biol.
Chem. 279, 7147-7158.
Sakurai, T., Dorr, N. P., Takahashi, N., McInnes, L. A., Elder, G. A. and Buxbaum,
J. D. (2011). Haploinsufficiency of Gtf2i, a gene deleted in Williams Syndrome, leads
to increases in social interactions. Autism Res. 4, 28-39.
Tantin, D., Tussie-Luna, M. I., Roy, A. L. and Sharp, P. A. (2004). Regulation of
immunoglobulin promoter activity by TFII-I class transcription factors. J. Biol. Chem.
279, 5460-5469.
Tapia-Pa´ez, I., Tammimies, K., Massinen, S., Roy, A. L. and Kere, J. (2008). The
complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene
implicated in neuronal migration and dyslexia. FASEB J. 22, 3001-3009.
Tassabehji, M., Hammond, P., Karmiloff-Smith, A., Thompson, P., Thorgeirsson,
S. S., Durkin, M. E., Popescu, N. C., Hutton, T., Metcalfe, K., Rucka, A. et al.
(2005). GTF2IRD1 in craniofacial development of humans and mice. Science 310,
1184-1187.
Thompson, J. D., Higgins, D. G. and Gibson, T. J. (1994). CLUSTAL W: improving
the sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids
Res. 22, 4673-4680.
Tipney, H. J., Hinsley, T. A., Brass, A., Metcalfe, K., Donnai, D. and Tassabehji, M.
(2004). Isolation and characterisation of GTF2IRD2, a novel fusion gene and member
of the TFII-I family of transcription factors, deleted in Williams-Beuren syndrome.
Eur. J. Hum. Genet. 12, 551-560.
Vullhorst, D. and Buonanno, A. (2003). Characterization of general transcription factor
3, a transcription factor involved in slow muscle-specific gene expression. J. Biol.
Chem. 278, 8370-8379.
Vullhorst, D. and Buonanno, A. (2005). Multiple GTF2I-like repeats of general
transcription factor 3 exhibit DNA binding properties. Evidence for a common origin
as a sequence-specific DNA interaction module. J. Biol. Chem. 280, 31722-31731.
Young, E. J., Lipina, T., Tam, E., Mandel, A., Clapcote, S. J., Bechard, A. R.,
Chambers, J., Mount, H. T., Fletcher, P. J., Roder, J. C. et al. (2008). Reduced
fear and aggression and altered serotonin metabolism in Gtf2ird1-targeted mice.
Genes Brain Behav. 7, 224-234.
Zhao, Y., Kwon, S. W., Anselmo, A., Kaur, K. and White, M. A. (2004). Broad
spectrum identification of cellular small ubiquitin-related modifier (SUMO) substrate
proteins. J. Biol. Chem. 279, 20999-21002.
Journal of Cell Science 125 (21)5050
